Janssen’s Talvey adds European approval on top of its US authorisation
Janssen’s bispecific antibody received conditional approval as a subcutaneous therapy based on Phase I/II trial data.
Janssen’s bispecific antibody received conditional approval as a subcutaneous therapy based on Phase I/II trial data.
What's Your Reaction?
